Description: ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In addition, the company develops peptide synthesis technologies. Further, it develops and manufactures western medicines and other chemical materials, albumin medicines, oligonucleotide medicines, injections, and new small molecule drugs, as well as provides biological technology services and technical services. It has a strategic alliance with Baxter International Inc. to develop, manufacture, and commercialize of antiemetic drug in chemotherapy for cancer. ScinoPharm Taiwan, Ltd. was incorporated in 1997 and is headquartered in Tainan City, Taiwan.
Home Page: www.scinopharm.com
No. 1, Nan-Ke 8th Road
Tainan City,
74144
Taiwan
Phone:
886 6 505 2888
Officers
| Name | Title |
|---|---|
| Mr. Chih-Hsien Lo | Chairman & Gen. Chief Strategy Officer |
| Ms. Li-An Lu | Pres & CEO |
| Ms. Chih-Hui Lin | Acting Financial Off., Sr. Director of Acct., Acct. Off., Acting Spokesperson & Corp. Gov. Off. |
| Mr. Ling-Hsiao Lien | Vice-Pres of Operations |
| Dr. Li-Chiao Chang Chemistry, Ph.D. | VP of R&D Division and Chief Scientific Officer |
| Mr. Jason Chen | Director of HR & Admin |
| Dr. Ching-Wen Lin B.S, M.S, Ph.D. | VP of Marketing & Sales and Chief Strategy Officer |
| Mr. Shun Yang Lin | Director of Corp. Devel. |
Exchange: TW
Country: TW : Taiwan
Currency: New Taiwan Dollar (NT$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 65.2564 |
| Price-to-Book MRQ: | 1.9168 |
| Price-to-Sales TTM: | 6.9014 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |